Most people with diabetes who take an injection of a GLP-1 drug will experience greater insulin sensitivity
Diabetes Care 2016;39(11): 19481955
The implication is that more agonism is better is going to age very poorly as a default assumption, and any clinician or biohacker still defaulting to it in 2030 is going to look like the cardiologists who were still reaching for first-generation beta-blockers in 1995
This is why people with significant fat to lose see dramatic results on semaglutide
Some obesity-medicine experts have called the drug a "game changer." Research has found it can lead to a 15% to 20% reduction in body weight over 68 weeks when paired with a reduced-calorie diet and regular exercise
The Obesity Medicine Association defines obesity as a chronic, relapsing, multifactorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences. Unfortunately, according to a U.S
:format(webp))
